Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193619 · ClinicalTrials.gov registry record
Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon
A clinical trial, sponsored by C. R. Bard.
- Completed
- Registry status
- 350
- Enrollment target
NCT03193619: Completed study, sponsored by C. R. Bard.
NCT03193619 is a clinical trial that has completed, run by C. R. Bard. The registered enrollment target is 350 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03193619 has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- 350 participants
- Enrollment target
Study Summary
The objective of this study is to assess the clinical use of the Bard® UltraScore™ Focused Force PTA balloon in a heterogeneous patient population in a real world, on-label clinical application.
Primary Outcome
Optimal result is defined as ≤30% residual stenosis without major flow-limiting dissection, as measured by angiographic imaging. Major flow limiting dissections are classified by the National Heart, Lung, and Blood Institute (NHLBI) as Grade D (Spiral luminal filling defects), Grade E (Appearance of new and persistent filling defects with reduced flow), and Grade F (Total occlusion without distal flow).
Interventions
- DEVICE PTA (UltraScore Focused Force PTA Balloon)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2022-04-01 |
What the finished NCT03193619 record still lists
NCT03193619 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PTA (UltraScore Focused Force PTA Balloon) is the first listed.
NCT03193619 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03193619 about?
NCT03193619 is a clinical study titled "Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon". The objective of this study is to assess the clinical use of the Bard® UltraScore™ Focused Force PTA balloon in a heterogeneous patient population in a real world, on-label clinical application.
What is the current status of trial NCT03193619?
This trial is currently completed. The enrollment target is 350 participants. The study started on 2018-03-28. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03193619?
The interventions under investigation include: PTA (UltraScore Focused Force PTA Balloon) (DEVICE).
Who is sponsoring clinical trial NCT03193619?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI